| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | SB-225002 | CTRPv2 | pan-cancer | AAC | 0.09 | 0.004 |
| mRNA | Doxorubicin | gCSI | pan-cancer | AAC | 0.16 | 0.004 |
| mRNA | rigosertib | CTRPv2 | pan-cancer | AAC | 0.095 | 0.005 |
| mRNA | SID 26681509 | CTRPv2 | pan-cancer | AAC | 0.11 | 0.005 |
| mRNA | lapatinib | GDSC1000 | pan-cancer | AAC | -0.14 | 0.005 |
| mRNA | NVP-231 | CTRPv2 | pan-cancer | AAC | 0.092 | 0.006 |
| mRNA | TAE684 | GDSC1000 | pan-cancer | AAC | -0.15 | 0.006 |
| mRNA | Cytarabine | CTRPv2 | pan-cancer | AAC | 0.079 | 0.006 |
| mRNA | TKI258 | CCLE | pan-cancer | AAC | 0.13 | 0.006 |
| mRNA | doxorubicin:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.091 | 0.006 |